Emergent Biosolutions
EBS • NYSE
Emergent Biosolutions is a drug manufacturers - specialty & generic company in the healthcare sector trading on NYSE, led by CEO Joseph C. Papa Jr., with a market cap of $436.4M.
Market Cap$436.4M
Employees1.6K
CEOJoseph C. Papa Jr.
CountryUnited States of America
Healthcare
Drug Manufacturers - Specialty & Generic
Next EarningsMay 6, 2026 · In 3 weeksQ1 2026
Financials
Emergent Biosolutions FAQ
Common questions about Emergent Biosolutions
Emergent Biosolutions is scheduled to report earnings for Q1 2026 on May 6, 2026. Analysts estimate revenue of $160.5M.
Emergent Biosolutions has approximately 1,600 employees.